DOCSLIB.ORG

Mark E. Shirtliff, Ph.D

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mark E. Shirtliff, Ph.D Mark E. Shirtliff, Ph.D. Associate Professor, Department of Microbial Pathogenesis, School of Dentistry, Univ. of Maryland–Baltimore, Baltimore, Maryland, U.S.A. Associate Professor, Department of Microbiology and Immunology, School of Medicine, Univ. of Maryland–Baltimore, Baltimore, Maryland, U.S.A. October 17, 2015 CONTACT INFORMATION Department of Microbial Pathogenesis, School of Dentistry, Univ. of Maryland-Baltimore 650 W. Baltimore Street, 8th Floor South Office: 9209; Lab: 9414 Baltimore, Maryland, U.S.A. 21201 Tel. (410) 706-2263 FAX (410) 706-0865 Email: [email protected] EDUCATION January 2001 - Ph.D. in Microbiology and Immunology Univ. of Texas Medical Branch, Galveston, TX, USA Dissertation Title, “Staphylococcus aureus: Roles in Osteomyelitis” Advisor: Dr. JT Mader May 1993 - B.S. (Cum Laude Honors) Univ. of Houston - Clear Lake, Houston, TX, USA Junior and Senior Years Major: Biology; Minor: Geography & Univ. of Alberta, Edmonton, AB, Canada Freshman and Sophomore Years Major: Biology; Minor: Geography EMPLOYMENT HISTORY Academic /Administrative Appointments in Higher Education Associate Professor with Tenure (Primary Appointment) Baltimore, MD Department of Microbial Pathogenesis July 2009 - present School of Dentistry, Univ. of Maryland – Baltimore Adjunct Associate Professor (Secondary Appointment) Baltimore, MD Department of Microbiology and Immunology Jan 2010 - present School of Medicine, Univ. of Maryland – Baltimore Assistant Professor Baltimore, MD Department of Microbial Pathogenesis Sept 2003 – July 2009 Department of Biomedical Sciences (Div. of Microbial Pathogenesis) School of Dentistry, Univ. of Maryland – Baltimore Mark E. Shirtliff, Ph.D. EMPLOYMENT HISTORY, Academic /Administrative Appointments in Higher Education…continued Adjunct Assistant Professor Baltimore, MD Department of Microbiology and Immunology Jan 2004 – Jan 2010 School of Medicine, Univ. of Maryland – Baltimore Assistant Research Professor Bozeman, MT Department of Microbiology & Oct 2002 - Aug 2003 The Center for Biofilm Engineering Montana State Univ. Advisor: Dr. J. W. Costerton Postdoctoral Fellow Bozeman, MT Center for Biofilm Engineering Oct 2000 - Oct 2002 Montana State Univ. Advisor: Dr. AK Camper Graduate Student and Research Assistant Galveston, TX Dept. of Microbiology and Immunology Jan 1997 - Sept 2000 U of Texas Medical Branch Coadvisor: Dr. DW Niesel Graduate Student and Laboratory Director Galveston, TX Dept. of Marine Biomedical Institute Sept 1995 - Sept 2000 U of Texas Medical Branch Advisor: Dr. JT Mader Laboratory Director Galveston, TX Dept. of Marine Biomedical Institute April 1995 - Sept 2000 U of Texas Medical Branch Advisor: Dr. JT Mader Research Assistant Galveston, TX Dept. of Microbiology and Immunology June 1993 - April 1995 U of Texas Medical Branch Supervisor: Dr. CP Davis Experience other than Higher Education Industry Consultant Goodell, Devries, Leech, & Dan, LLP. 2012 – Present. Stryker Inc. 2002 – Present. Sedgewick, LLP. 2012 – 2013. Twin Star Medical. 2012. Atrium Medical Corporation. 2012. Affinergy. 2008. Shook, Hardy, and Bacon. 2007 – 2009. Microbiotix. 2006 – 2008. Targanta. 2006. Synthes. 2005 – 2007. Howmedica. 2002 – 2004. Genome Therapeutics. 2002. 2 Mark E. Shirtliff, Ph.D. Major Teaching Responsibilities in Higher Education Undergraduate: Lecturer, BIO354 – Microbiology and Immunology, Goucher College. Fall, 2010 – 2014. Lecturer, Molecular Techniques - Bioprocesses in Engineering. College of Engineering, Montana State Univ. Spring, 2002. Supervision and mentoring of >40 undergraduate and post-graduate students in laboratory Graduate: Director, Oral Examination Committee, Molecular Microbiology and Immunology, Graduate Program in Life Sciences, Univ. of Maryland, Baltimore. 57 Hours/yr. 12 Students. Spring 2015 – present. Course Director and Instructor, MICP 521 – General & Orofacial Infectious Diseases, Univ. of Maryland, Baltimore. 4.5 Hours/yr. 130 Students. Fall, 2009 – present. Course Director and Instructor, MICP 521a – Translational Research Conferences on General & Orofacial Infectious Diseases, Univ. of Maryland, Baltimore. 20 Hours/yr. 260 Students. Fall, 2009 – present. Instructor, GPLS725 – Advanced Microbial Pathogenesis, Graduate Program in Life Sciences, Univ. of Maryland, Baltimore. 3 Hours/yr. Fall, 2011 – present. Course Director and Instructor, GPLS710 – Principles of Microbial Pathogenesis, Graduate Program in Life Sciences, Univ. of Maryland, Baltimore. 4 Hours/yr. Spring, 2005 – present. Instructor, MCO506 – Prokaryotic and Eukaryotic Cell Biology and Genetics, Uniformed Services Univ., Washington D.C. 4 Hours/yr. Fall, 2014 – present. Instructor, MCO503 – Cellular and Molecular Immunology, Uniformed Services Univ., Washington, D.C. 2 Hours/yr. Fall, 2012 – present. Instructor, MSPR 520 – Host Defenses and Infectious Diseases, Univ. of Maryland, Baltimore. 1 Hour/yr. Fall, 2010 – present. Instructor, BSCI 518C – Case Based Conferences, Univ. of Maryland, Baltimore. 3 Hours/yr. Fall, 2008 – present. Instructor, MSPR 520 – Host Defenses and Infectious Diseases, Small Group Study, Univ. of Maryland, Baltimore. 1.5 Hours/yr. Fall, 2006 – present. Instructor, ODSC-511C – (Previously BSCI-511) – Cell and Molecular Biology, Univ. of Maryland, Baltimore. 1 Hour/yr. Fall 2006 – present. Instructor, MICP511 (Previously DBMS 511M) – Microbiology and Immunology, Univ. of Maryland, Baltimore. 2 Hours/yr Spring 2004 - present. Instructor, MCB 602 – Molecular Cell Biology, Univ. of Maryland, Baltimore. Spring, 2006. Instructor, DBMS 619 – Seminars in Biomedical Sciences, Univ. of Maryland, Baltimore. Fall, 2005 – 2009. Instructor, DBMS 635 – Bacterial Genetics, Univ. of Maryland, Baltimore. Fall 2004 – 2008. Instructor, DBMS 604 – Introduction to Biomedical Sciences, Univ. of Maryland, Baltimore. Fall 2004 –2007. Instructor, DPDM 518 – Asepsis Microbiology Assessment, Univ. of Maryland, Baltimore. Fall, 2004. Instructor, Proteomics: Methods and Applications Workshop. La Sapienza Univ., Rome, Italy. March 27 – April 7, 2004. Instructor, Biofilms Techniques Workshop. Univ. of Concepcion, Concepcion, Chile. January 8 – 20, 2004. 3 Mark E. Shirtliff, Ph.D. Major Teaching Responsibilities in Higher Education…continued. Graduate…continued: Lecturer, Molecular Techniques, Veterinary Molecular Biology, Montana State Univ., Spring, 2003. Lecturer, A Course in Biocompatibility, Aalborg Univ., Denmark, April 7-9, 2003. Laboratory Instructor, Medical Microbiology, Department of Microbiology and Immunology, Univ. of Texas Medical Branch. 1998. Laboratory Instructor, Medical Microbiology, Department of Microbiology and Immunology, Univ. of Texas Medical Branch. 1997. International Graduate: Instructor, Bacterial Biofilms and Their Role in Chronic Infections. The Panum Institute, Faculty Of Health Sciences, Univ. of Copenhagen, Copenhagen, Denmark. 20 Hours/yr. Fall, 2012 – present. Instructor, The Host Immune Response to Candida albicans Infections. Microbiology and Immunology. The Panum Institute, Faculty Of Health Sciences, Univ. of Copenhagen, Copenhagen, Denmark. 2 Hours/yr. Fall, 2014 – present. HONORS Teaching Commendation in Host Defenses and Infectious Diseases by the Class of 2016, University of Maryland School of Medicine. 2013. Outstanding Researcher of the Year, Center Biofilm Engineering 2002. Christina Fleischmann Award, U of TX Medical Branch. 2000. Curtis W. Lambert Academic Scholarship Award, U of TX Medical Branch (2000) Arthur V. Simmang Academic Scholarship, U of TX Medical Branch (1999) Elected to Sigma Xi scientific honors society (1998) Cum Laude Honors, Univ. of Houston (1994) Information Sciences Academic Scholarship, Univ. of Houston (1993) PRODUCTIVITY MEASURES h-index = 36 The h-index is an index that attempts to measure both the productivity and impact of the published work of a scientist or scholar. The index is based on the set of the scientist's most cited papers and the number of citations that they have received in other publications. I-10 index = 71 The i10-index indicates the number of academic publications an author has written that have at least ten citations. Citations = 5562 4 Mark E. Shirtliff, Ph.D. PROFESSIONAL ACTIVITIES AND SERVICE Local and National Service: Local: President, American Society for Microbiology, Maryland Division. 2007 –2008. Graduate Council, Univ. of Maryland, Baltimore and Univ. of Maryland, Baltimore County. 2007 – 2008. Presenter, Univ. of Maryland School of Dentistry, 20th Annual High School Biomedical Research Program. Univ. of Maryland, Baltimore. 2008. Seminar Coordinator, Department of Biomedical Sciences. School of Dentistry. Univ. of Maryland, Baltimore. 2005 – 2008. Center for Biofilm Engineering Seminar Coordinator. 2000 – 2003. President, Forest Bend Fire Department. 1997 - 1998, 1999 - 2000. President, Theta Chi Fraternity. 1989 - 1990. National: Meeting Organizing Committee. European Society of Clinical Microbiology and Infectious Diseases. Instanbul, Turkey. April 9-14, 2016. Meeting Organizing Committee. ASM Animal Workshop, American Society for Microbiology, 7th Conference on Biofilms. Chicago, IL. October 24-29, 2015. Meeting Organizing Committee. 1st ASM Conference on Polymicrobial Infections. Washington, DC. November 13-16, 2014. Professional Society Membership: International Society of Microbial Ecology. 2005 – present. American Society for Microbiology – Maryland Branch. 2004 – present. Member, Sigma Xi (elected). 1998 – present. American Society for Microbiology. 1998 – present. Editorial
Load more

Recommended publications
  • Editorial Note on Medical Microbiology & Diagnosis – Clinical
    Manuscript no.- JMMD-2021-5 Article type- Editorial Received date- 20-01-2021 Accepted- 20-01-2021 Publish date-23-01-2021 Editorial Note on Medical Microbiology & Diagnosis – Clinical Microbial Pathology Tirpude RJ Defence Institute of Physiology and Allied Sciences Address for Correspondence: Tirpude RJ, Defence Institute of Physiology and Allied Sciences, Delhi - 110054, India. Tel-9869217101, E-mail: [email protected] Editorial Clinical pathology is concerned with the diagnosis of disease based on laboratory analysis of body fluids like urine and blood. It deals with the tools of microbiology like macroscopic, microscopic, analyzers and cultures. It covers microbiology, host-pathogen interaction and immunology related to infectious agents, including bacteria, fungi, viruses and protozoa. It also accepts papers in the field of clinical microbiology, with the exception of case reports. The pathogenesis of a disease is the biological mechanism that leads to the diseased state. It also describes the origin and development of the disease, and whether it is acute, chronic, or recurrent. Medical microbiology involves the identification of microorganisms for the diagnosis of infectious diseases and the assessment of likely response to specific therapeutic interventions. Major categories of organisms include bacteria, mycobacteria, fungi, viruses, and parasites. Microbiological methods combined with clinical symptoms, additional laboratory tests, and imaging techniques are used in combination to distinguish a true disease- associated infection from colonization with normal flora or other conditions, such as malignancies, inflammatory disorders, or autoimmune disorders, all of which have unique therapies and prognoses for the patient. Laboratories combine the use of traditional microscopy and culture methods, with a rapidly evolving set of molecular and proteomic techniques.
    [Show full text]
  • Anika Anthony, Associate Dean of Academic Affairs, Graduate School
    TO: Randy Smith, Vice Provost for Academic Programs FROM: Anika Anthony, Associate Dean of Academic Affairs, Graduate School DATE: January 21,2021 RE: Proposal for a new Master of Science in Immunology ad Microbial Pathogenesis, College of Medicine The College of Medicine is proposing a new Master of Science in Immunology and Microbial Pathogenesis. The proposal was received by the Graduate School on November 6, 2020. The combined GS/CAA subcommittee first reviewed the proposal on November 17, 2020 and requested revisions. Revisions were received on December 2, 2020. GS/CAA conducted a second review of the proposal and recommended it for approval by the Graduate Council on December 9. The proposal was approved by the Graduate Council on January 11, 2021. Mark E. Drew Assistant Professor Director of Graduate Education Department of Microbial Infection and Immunity OSU College of Medicine December 2, 2020 GS/CAA curricular subcommittee Ohio State University Re: Master of Science (MS) in Immunology and Microbial Pathogenesis Dear Members of the Subcommittee, Thank you for your kind and positive review of our proposal to offer a new Master of Science in Immunology and Microbial Pathogenesis program at OSU. Your comments and suggestions were extremely helpful in refining the proposal. Specifically, in response to your comments, we have made the following changes: 1. “Clarity on which courses are new vs. those that are already existing.” Page 34 of the proposal now includes brief descriptions of the three courses under development to support this program in our expectation of its approval. The complete syllabi are being developed by four key program faculty (Drew, Deora, Root, Novias) with planned entry into the new course portal on or before January 1, 2021.
    [Show full text]
  • Microbiology (MICROB) 1
    Microbiology (MICROB) 1 Credit Hours: 3 Microbiology (MICROB) Recommended: MICROB 3200 or BIOCHM 4270 or MICROB 2800 MICROB 2800: Microbiology for Nursing and Health Professions MICROB 7101: Structure and Synthesis of Macro Molecules This course will provide basic principles for understanding microbial This multiple-instructor course is designed to provide students with growth, function, and control. This includes a survey of microbial cellular a detailed understanding of the structure, function, and biophysical structure/functions, immunology concepts, epidemiology, specimen properties of bio-molecules. Principles and techniques of molecular handling, and causes of microbial disease (bacterial, viral, and parasitic). biology related to the study of recombinant DNA and genetic analysis, Material is presented in lecture and corresponding laboratory exercises protein structure, function and basic immunological principles will be that will allow students to explore the microbial world around them. covered. Admission is dependent on approval by course director. Credit Hours: 4 Credit Hours: 2 Prerequisites: The overall content is "restricted to Freshman and Prerequisites: consent required sophomore Nursing and Health Related Professional students only". Other inquires contact department MICROB 8050: Graduate Student Survival Skills This course is an introduction to inform new graduate students about the MICROB 3200: Medical Microbiology and Immunology Microbiology program and provide them with the knowledge to access Focus on medically important viruses, bacteria, fungi and parasites resources and information needed for a successful transition into their with emphasis on their disease causing potential and mechanisms. course work and research. The course will also focus on guidelines Introduction to cells and molecules of the immune system with emphasis in selecting mentors and their relationships, time management, good on their role in fighting infectious diseases.
    [Show full text]
  • Department of Microbiology, Immunology, and Cell Biology
    Immunology and Microbial Pathogenesis Graduate Program WEST VIRGINIA UNIVERSITY HEALTH SCIENCES CENTER Doctor of Philosophy in Immunology and Microbial Pathogenesis Goals and Objectives The major objective of graduate education in the Immunology and Microbial Pathogenesis Graduate Program is research training. To achieve this purpose, students are grounded with a strong foundation in basic concepts of microbiology, microbial pathogenesis, and immunology and allowed flexibility in choosing advanced coursework in their specific areas of interest. A major emphasis of the advanced coursework in the graduate program is extensive laboratory research in a specific area of immunology or microbial pathogenesis. Each student will complete an original, in-depth research investigation and document that investigation in the form of a written dissertation. The overall educational objective of the program is to produce doctoral students capable of designing, performing, and directing independent research in Immunology and Microbial Pathogenesis as well as teach at the highest academic levels. The mission of West Virginia University and the Graduate Program in Immunology and Microbial Pathogenesis is to provide excellence in education, research, and service to the State of West Virginia. The cornerstone to achieving this mission is a sustained research program that is internationally recognized as contributing to state-of-the-art knowledge in each of the sub disciplines of the program. This research expands knowledge necessary to provide new state-of-the-art treatments for our patients, develops in our students the knowledge base and skills necessary to mature to become independent investigators, and allows our faculty to contribute to the overall service mission of the university.
    [Show full text]
  • Mammalian Neuropeptides As Modulators of Microbial Infections: Their Dual Role in Defense Versus Virulence and Pathogenesis
    International Journal of Molecular Sciences Review Mammalian Neuropeptides as Modulators of Microbial Infections: Their Dual Role in Defense versus Virulence and Pathogenesis Daria Augustyniak 1,* , Eliza Kramarska 1,2, Paweł Mackiewicz 3, Magdalena Orczyk-Pawiłowicz 4 and Fionnuala T. Lundy 5 1 Department of Pathogen Biology and Immunology, Faculty of Biology, University of Wroclaw, 51-148 Wroclaw, Poland; [email protected] 2 Institute of Biostructures and Bioimaging, Consiglio Nazionale delle Ricerche, 80134 Napoli, Italy 3 Department of Bioinformatics and Genomics, Faculty of Biotechnology, University of Wroclaw, 50-383 Wroclaw, Poland; pamac@smorfland.uni.wroc.pl 4 Department of Chemistry and Immunochemistry, Wroclaw Medical University, 50-369 Wroclaw, Poland; [email protected] 5 Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast BT9 7BL, UK; [email protected] * Correspondence: [email protected]; Tel.: +48-71-375-6296 Abstract: The regulation of infection and inflammation by a variety of host peptides may represent an evolutionary failsafe in terms of functional degeneracy and it emphasizes the significance of host defense in survival. Neuropeptides have been demonstrated to have similar antimicrobial activities to conventional antimicrobial peptides with broad-spectrum action against a variety of microorganisms. Citation: Augustyniak, D.; Neuropeptides display indirect anti-infective capacity via
    [Show full text]
  • Virulence Factors and Their Mechanisms of Action: the View from a Damage–Response Framework Arturo Casadevall and Liise-Anne Pirofski
    S2 Q IWA Publishing 2009 Journal of Water and Health | 07.S1 | 2009 Virulence factors and their mechanisms of action: the view from a damage–response framework Arturo Casadevall and Liise-anne Pirofski ABSTRACT The virulence factor concept has been a powerful engine in driving research and the intellectual Arturo Casadevall (corresponding author) Liise-anne Pirofski flow in the fields of microbial pathogenesis and infectious diseases. This review analyzes Division of Infectious Diseases, virulence factors from the viewpoint of the damage–response framework of microbial Department of Medicine and the Department of Microbiology and Immunology of the Albert pathogenesis, which defines virulence factor as microbial components that can damage a Einstein College of Medicine, 1300 Morris Park Avenue, susceptible host. At a practical level, the finding that effective immune responses often target Bronx NY 10461, USA virulence factors provides a roadmap for future vaccine design. However, there are significant Tel.: +1 718 430 2215 limitations to this concept, which are rooted in the inability to define virulence and virulence Fax: +1 718 430 8968 E-mail: [email protected] factors in the absence of host factors and the host response. In fact, this concept appears to work best for certain types of bacterial pathogens, being less well suited for viruses and commensal organisms with pathogenic potential. Key words | damage–response framework, microbe, pathogen, pathogenicity, virulence, virulence factor INTRODUCTION The idea that pathogenic microbes are endowed with understanding of microbial virulence. In this paper, we certain components that confer upon them the capacity review the historical context for the emergence of the for virulence is the central theme of the virulence factor virulence factor concept and then consider it from concept.
    [Show full text]
  • Microbial Pathogenesis Rafael Rotger2
    INTERNATL MICROBIOL (1999) 2:131–132 131 © Springer-Verlag Ibérica 1999 EDITORIAL José A. Vázquez-Boland1 Mónica Suárez1 Microbial pathogenesis Rafael Rotger2 1Molecular Bacterial Pathogenesis Group, Department of Animal Pathology I, Faculty of Veterinary Medicine, Complutense University of Madrid, Spain 2Department of Microbiology, Faculty of Pharmacy, Complutense University of Madrid, Spain Correspondence to: José A. Vázquez-Boland. Molecular Bacterial Pathogenesis Group. Department of Animal Pathology I. Faculty of Veterinary Medicine. Complutense University of Madrid. 28040 Madrid. Spain. Tel.: +34-913943704. Fax: +34-913943908. E-mail: [email protected] The last two decades of the nineteenth century marked a period unable to predict any function for some 30% of the putative genes of true revolution, in which the foundations were laid for the present in the sequenced genomes, which shows that we are still development of microbiology as a scientific and medical discipline. far from understanding, in functional terms, many aspects of the It was during these years that most of the major bacterial agents biology of microorganisms. Clearly, the years to come will define of infection known today were discovered. Deadly bacteria such a post-genomic era in which emphasis will be placed on the as pneumococci and meningococci, and the agents of typhoid development of instruments and technologies for the systematic fever, cholera, tuberculosis, tetanus, gas gangrene, bacillary functional analysis of the overwhelming mass of genetic dysentery and plague, were all isolated between 1880 and 1898. information that will be available for study and exploitation. If we consider that only a few years before Louis Pasteur had The introduction of DNA techniques into the study of proved that the theory of spontaneous generation was incorrect pathogenic microorganisms opened the way to the molecular (1860), and that Robert Koch, in his studies of anthrax in cattle analysis of virulence.
    [Show full text]
  • Autophagy and Microbial Pathogenesis
    Cell Death & Differentiation (2020) 27:872–886 https://doi.org/10.1038/s41418-019-0481-8 REVIEW ARTICLE Autophagy and microbial pathogenesis 1,2 2 1,2,3 Matthew D. Keller ● Victor J. Torres ● Ken Cadwell Received: 12 October 2019 / Revised: 4 December 2019 / Accepted: 6 December 2019 / Published online: 2 January 2020 © The Author(s), under exclusive licence to ADMC Associazione Differenziamento e Morte Cellulare 2020 Abstract Autophagy is a cell biological process that promotes resilience in the face of environmental perturbations. Given that infectious agents represent a major type of environmental threat, it follows that the autophagy pathway is central to the outcome of host–microbe interactions. Detailed molecular studies have revealed intricate ways in which autophagy suppresses or enhances the fitness of infectious agents, particularly intracellular pathogens such as viruses that require the host cell machinery for replication. Findings in animal models have reinforced the importance of these events that occur within individual cells and have extended the role of autophagy to extracellular microbes and immunity at the whole organism level. These functions impact adaptation to bacteria that are part of the gut microbiota, which has implications for the etiology of chronic disorders such as inflammatory bowel disease. Despite major advances in how autophagy regulates inflammatory reactions toward microbes, many challenges remain, including distinguishing autophagy from closely related pathways such as LC3-associated phagocytosis. Here, we review 1234567890();,: 1234567890();,: the role of autophagy in microbial pathogenesis at the level of organismal biology. In addition to providing an overview of the prominent function of autophagy proteins in host–microbe interactions, we highlight how observations at the cellular level are informing pathogenesis studies and offer our perspective on the future directions of the field.
    [Show full text]
  • What Is Infectiveness and How Is It Involved in Infection and Immunity? Liise-Anne Pirofski1,2* and Arturo Casadevall2
    Pirofski and Casadevall BMC Immunology (2015) 16:13 DOI 10.1186/s12865-015-0076-1 REVIEW Open Access What is infectiveness and how is it involved in infection and immunity? Liise-anne Pirofski1,2* and Arturo Casadevall2 Abstract Proof of the Germ theory of disease and acceptance of Koch’s postulates in the late 1890’s launched the fields of microbial pathogenesis and infectious diseases and provided the conceptual framework that has guided thought and research in these fields. A central tenet that emerged from studies with microbes that fulfilled Koch’s postulates was that microbes that caused disease had characteristics that allowed them to do so, with the corollary that microbes that did not cause disease lacked disease-causing determinants. This observation, which held true for many diseases that were known to cause disease in the late 19th century, such as toxin-producing and encapsulated bacteria, led to the view that the ability to cause disease rested with microbes and reflected the activity of specific determinants, or virulence factors. With the dawn of the 20th century, efforts to neutralize virulence factors were under development and ultimately translated into anti-microbial therapy in the form of antibodies targeted to toxins and polysaccharide capsules. However, the 20th century progressed, antibiotics were identified and developed as therapy for infectious diseases while other medical advances, such as specialized surgeries, intensive care units, intravenous catheters, and cytotoxic chemotherapy became commonplace in resourced nations. An unintended consequence of many of these advances was that they resulted in immune impairment. Similarly, HIV/AIDS, which emerged in the late 1970’s also produced profound immune impairment.
    [Show full text]
  • Veterinary Microbiology and Preventive Medicine (V MPM) 1
    Veterinary Microbiology and Preventive Medicine (V MPM) 1 V MPM 388: Public Health and the Role of the Veterinary Profession VETERINARY MICROBIOLOGY (3-0) Cr. 3. S. AND PREVENTIVE MEDICINE Prereq: Second-year classification in veterinary medicine Fundamental epidemiology, zoonotic diseases, occupational health, food (V MPM) safety, other public health topics. Any experimental courses offered by V MPM can be found at: V MPM 390: Topics in Veterinary History registrar.iastate.edu/faculty-staff/courses/explistings/ (http:// (1-0) Cr. 1. F.S. www.registrar.iastate.edu/faculty-staff/courses/explistings/) An overview of the history of veterinary medicine focused primarily on disease-specific events. A review of the historical aspects of the Courses primarily for professional curriculum students: veterinary profession's accomplishments in the discovery of the V MPM 360: Global Health etiological origins of disease and their subsequent control will provide (Cross-listed with GLOBE, MICRO). (3-0) Cr. 3. F. students with insights that are applicable to understanding and solving Prereq: BIOL 211 today's animal and human health challenges. Explores human health across the world with particular emphasis V MPM 428: Principles of Epidemiology and Population Health on low- and lower-middle-income countries. Attention is given to the (Dual-listed with V MPM 528). (Cross-listed with MICRO, VDPAM). (3-0) Cr. interconnectedness of health determinants, problems, and solutions 3. S. found in global health, including the role of animals and the environment. Epidemiology of disease in populations. Disease causality, observational Broad in scope, highlighting different cultures and the historical study design and approaches to epidemiologic investigations.
    [Show full text]
  • The State of Latency in Microbial Pathogenesis
    The Journal of Clinical Investigation REVIEW SERIES: LATENCY IN INFECTIOUS DISEASE Series Editor: Arturo Casadevall The state of latency in microbial pathogenesis Liise-anne Pirofski1 and Arturo Casadevall2 1Division of Infectious Diseases, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA. 2Department of Molecular Microbiology and Immunology, Johns Hopkins School of Public Health, Baltimore, Maryland, USA. The state of latency occurs when a microbe’s persistence in a host produces host damage without perturbing homeostasis sufficiently to cause clinical symptoms or disease. The mechanisms contributing to latency are diverse and depend on the nature of both the microbe and the host. Latency has advantages for both host and microbe. The host avoids progressive damage caused by interaction with the microbe that may translate into disease, and the microbe secures a stable niche in which to survive. Latency is clinically important because some latent microbes can be transmitted to other hosts, and it is associated with a risk for recrudescent microbial growth and development of disease. In addition, it can predispose the host to other diseases, such as malignancies. Hence, latency is a temporally unstable state with an eventual outcome that mainly depends on host immunity. Latency is an integral part of the pathogenic strategies of microbes that require human (and/ or mammalian) hosts, including herpesviruses, retroviruses, Mycobacterium tuberculosis, and Toxoplasma gondii. However, latency is also an outcome of infection with environmental organisms such as Cryptococcus neoformans, which require no host in their replicative cycles. For most microbes that achieve latency, there is a need for a better understanding and more investigation of host and microbial mechanisms that result in this state.
    [Show full text]
  • Chapter 1. Bacteria: Pathogenicity Factors
    I.1. BACTERIA: PATHOGENICITY FACTORS – 27 Chapter 1. Bacteria: Pathogenicity factors This chapter provides guidance on topics and issues relevant to the risk/safety assessment of commercial environmental applications involving genetically engineered micro-organisms, especially bacteria. It explores the important aspects in bacteria for causing adverse human health effects, and how this knowledge can be used in biosafety regulatory assessment. It contains information on bacterial pathogenicity (general considerations, factors and determinants, genetics and molecular biology), and also elements on assessing potential for bacteria-mediated adverse human health effects. The chapter was prepared by the OECD Working Group on the Harmonisation of Regulatory Oversight in Biotechnology, Sub-working Group on Micro-organisms, with the Netherlands and Canada having served as lead countries. It was initially issued in September 2011. SAFETY ASSESSMENT OF TRANSGENIC ORGANISMS: OECD CONSENSUS DOCUMENTS, VOLUME 5 © OECD 2016 28 – I.1. BACTERIA: PATHOGENICITY FACTORS General considerations for bacterial pathogenicity This chapter provides guidance on the concept of bacterial pathogenicity in the context of risk/safety assessment of deliberate release of “genetically engineered”, or “genetically modified”,1 micro-organisms intended for commercial environmental applications (e.g. bioremediation, biosensors, biofertilisers, biopesticides, biomining, biomass conversion or oil recovery). It is limited in scope to bacteria that may exhibit properties pathogenic to human beings. Not included in the scope are environmental releases of known (potential) pathogens, e.g. vaccine strains. The chapter explores the factors that are important in bacteria for causing adverse human health effects and assesses how this knowledge can be used in risk/safety assessment of environmental applications of bacteria.
    [Show full text]